Otonomy to Host Virtual Investor R&D Event on March 22, 2022
This event will include presentations by key opinion leaders who will provide background information on tinnitus and hearing loss, and review the positive Phase 1/2 trial results for Otonomy’s OTO-313 and OTO-413 product candidates that target these conditions. Additionally, members of Otonomy’s senior management team will provide an update on ongoing clinical trials and outline next steps for these programs.
External speakers participating in this event include:
Barbara Shinn-Cunningham, Ph.D., Director, Carnegie Mellon Neuroscience Instituteand Cowan Professorof Auditory Neuroscience, Biomedical Engineering, Psychology, and Electrical & Computer Engineering, Carnegie Mellon University Victoria Sanchez, Au.D., Ph.D., Assistant Professor, Department of Otolaryngology- Head & Neck Surgery, University of South Florida Anthony Mikulec, M.D., Professor of Otologic, Neurotologic and Skull Base Surgery, Department of Otolaryngology- Head and Neck Surgery, Saint Louis University John Phillips, Ph.D., MBBS, MRCS (Eng), FRCS (ORL-HNS), Consultant ENT Surgeon, Norfolk & Norwick University Hospitals NHS Foundation Trust, United Kingdom
To register for Otonomy’s Virtual Investor R&D Event, please sign up here. Registration for this event and access to the webcast will be available on the investor relations section of Otonomy’s website at Events |
Senior Account Executive
Source: Otonomy, Inc.